Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – The LORD study

Authors: Lotte E. Elshof, Konstantinos Tryfonidis, Leen Slaets, A. Elise van Leeuwen‐Stok, Victoria Skinner, Nicolas Dif, Ruud M. Pijnappel, Nina Bijker, Emiel J. Rutgers, Jelle Wesseling - European Journal of Cancer 2015 cited by 380